Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Pharmalink Initiates Phase IIb Trial with Nefecon®

Published: Friday, December 21, 2012
Last Updated: Friday, December 21, 2012
Bookmark and Share
Pharmalink expects to announce top line results in the first half of 2015.

Pharmalink AB has announced that it has initiated a Phase IIb study with Nefecon® (Nefigan) in patients with primary IgA nephropathy at risk of developing end-stage renal disease.

Nefecon is an enteric formulation of a locally acting corticosteroid that down-regulates the inflammatory process in the kidneys through suppression of the gastrointestinal immune system.

The study is a multi-center, randomized, double-blinded placebo controlled study to evaluate the efficacy and safety of two different doses of Nefecon in 90 primary IgA nephropathy patients at risk of end-stage renal disease.

The first patient was recently enrolled in the clinical trial, which will be conducted at approximately 50 participating centers across 10 European countries.

The primary objective will be to investigate whether patients on Nefecon have a larger mean reduction in proteinuria compared to patients on placebo. Pharmalink expects to announce top line results in the first half of 2015.

Nefecon showed positive results in an open-labelled Phase IIa trial evaluating safety and efficacy with 16 patients at trial centers in Sweden.

The final results of the study demonstrated a significant and clinically meaningful effect in the primary endpoint: reduction in proteinuria.

Significant results were also seen in secondary endpoints: reduction of serum creatinine and increase in glomerular filtration rates. Furthermore, Nefecon was well tolerated with few or no-drug related side effects.

IgA nephropathy is an orphan condition and Nefecon is aimed at providing patients with IgA nephropathy a disease modifying medication.

Alex Mercer, Clinical Development Director at Pharmalink, said: “IgA nephropathy is a disease with a high unmet medical need and no approved treatments available on the market today. Progression to renal failure has a terrible impact on patients’ quality of life and is a high burden to health care systems. Pharmalink hopes to bring a new medicine to patients for early treatment, halting disease progression and further loss of renal function. We look forward to confirming the highly promising results we have seen so far with Nefecon and to advancing the product in this pivotal phase IIb trial.”

Nefecon® is a patented invention by Professors Bengt Fellström and Roger Hällgren at Uppsala University (Sweden) and was acquired by Pharmalink in 2004.

Nefecon® is delivered using the proprietary TARGIT® drug delivery technology which enables the localized delivery of drugs to the lower small intestine or colonic regions of the gastrointestinal tract.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,300+ scientific posters on ePosters
  • More than 4,800+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Pharmalink AB Strengthens Senior Management Team
Dr. Heather Cook appointed director of regulatory affairs and Marek Poszepczynski as director of business development.
Thursday, February 21, 2013
Pharmalink Enters Manufacturing Agreement for Nefecon®
Company has entered into a contract with Patheon.
Thursday, November 01, 2012
Pharmalink AB Raises SEK 35 Million through Share Issue
New funds used to further advance Nefecon® and Busulipo™.
Friday, January 06, 2012
Scientific News
Viable HIV Vaccine Confirmed by Study
HIV Study in macaques confirms clinically viable vaccine opening the way for future treatment in humans.
PREVAIL Treatment Trial for Men with Persistent Ebola Viral RNA
The six-month study will enroll 60 to 120 EVD survivors.
What Makes a Good Scientist?
It’s the journey, not just the destination that counts as a scientist when conducting research.
Investigational Malaria Vaccine Protects Healthy U.S. Adults
Researchers at NIH have found that the malaria vaccine protected a small number of healthy, malaria-naïve adults in the U.S. from infection for more than one year after immunization.
AACR 2016: Cancer Immunotherapy and Beyond
At this year's meeting there was a palpable buzz around subjects ranging from microbiomics to the tumor microenvironment and cancer vaccines, big data to in vitro and in vivo modeling and drug delivery (to name just a few).
New Database for Sharing MS Clinical Trial Data
A new database containing nearly 2500 patient records from the placebo arms of nine multiple sclerosis (MS) clinical trials is now available for research by qualified investigators.
Study Finds Factors That May Influence Influenza Vaccine Effectiveness
Researchers at NIH have suggested that the long-held approach to predicting seasonal influenza vaccine effectiveness may need to be revisited.
BMS’s Opdivo Clinical Trial Shows Promise
Safety profile of the combination regimen from CheckMate -069 was consistent with previously reported studies and adverse events were managed using established safety algorithms.
Treatment of Common Prostate Cancer
Researchers at UTSW have found that the prostate cancer treatments suppress immune response and may promote relapse.
Cancer Drug Could Treat Blood Vessel Deformities
A drug currently being trialled in cancer patients could also be used to treat an often incurable condition that can cause painful blood vessel overgrowths inside the skin.
Scroll Up
Scroll Down
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,300+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,800+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!